Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Newly Diagnosed FLT3 Mutated AML”

26 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 26 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06667973
What this trial is testing

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaFLT3 Gene MutationAdult AML+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto 80
Testing effectiveness (Phase 2)UnknownNCT03135054
What this trial is testing

Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

Who this might be right for
AMLFLT3-ITD Mutation
The University of Hong Kong 40
Large-scale testing (Phase 3)Not Yet RecruitingNCT07407140
What this trial is testing

VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML

Who this might be right for
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China 300
Testing effectiveness (Phase 2)Looking for participantsNCT06561880
What this trial is testing

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Who this might be right for
FLT3 Gene MutationAML
Institute of Hematology & Blood Diseases Hospital, China 36
Large-scale testing (Phase 3)Study completedNCT03258931
What this trial is testing

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Who this might be right for
Newly Diagnosed FLT3 Mutated AML
Arog Pharmaceuticals, Inc. 214
Testing effectiveness (Phase 2)Study completedNCT01830361
What this trial is testing

Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML

Who this might be right for
Acute Myeloid Leukemia
Technische Universität Dresden 18
Large-scale testing (Phase 3)UnknownNCT00651261
What this trial is testing

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Who this might be right for
Leukemia
Alliance for Clinical Trials in Oncology 717
Large-scale testing (Phase 3)Not Yet RecruitingNCT07425808
What this trial is testing

FLT3-ITD Targeted Therapy in Fit AML Patients

Who this might be right for
AML (Acute Myeloid Leukemia)
European Organisation for Research and Treatment of Cancer - EORTC 230
Testing effectiveness (Phase 2)Study completedNCT02310321
What this trial is testing

ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Who this might be right for
Acute Myeloid LeukemiaFLT3-mutated Acute Myeloid Leukemia
Astellas Pharma Inc 97
Early research (Phase 1)Looking for participantsNCT05886049
What this trial is testing

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Who this might be right for
Acute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation
National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Looking for participantsNCT07259707
What this trial is testing

Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML

Who this might be right for
Acute Myeloid LeukemiaFLT3 Internal Tandem Duplication PositiveIntermediate Risk Acute Myeloid Leukemia+1 more
First Affiliated Hospital of Zhejiang University 25
Early research (Phase 1)Study completedNCT03900949
What this trial is testing

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Uma Borate 21
Early research (Phase 1)Ended earlyNCT03552029
What this trial is testing

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT05520567
What this trial is testing

Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)FLT3-mutated Acute Myeloid Leukemia
Astellas Pharma Global Development, Inc. 70
Testing effectiveness (Phase 2)Ended earlyNCT02634827
What this trial is testing

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With Gene MutationsFLT3 Tyrosine Kinase Domain Point Mutation+2 more
Mayo Clinic 1
Large-scale testing (Phase 3)Study completedNCT03512197
What this trial is testing

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia (AML)
Novartis Pharmaceuticals 511
Not applicableNo Longer AvailableNCT02624570
What this trial is testing

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Who this might be right for
Acute Myeloid Leukemia (AML) WithFLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT05010122
What this trial is testing

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+1 more
M.D. Anderson Cancer Center 42
Testing effectiveness (Phase 2)Looking for participantsNCT06317649
What this trial is testing

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Who this might be right for
Acute Myeloid Leukemia
National Cancer Institute (NCI) 147
Not applicableNo Longer AvailableNCT03114228
What this trial is testing

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

Who this might be right for
FLT3-mutated Acute Myeloid Leukemia
Novartis Pharmaceuticals
Load More Results